Alamar Biosciences and ALZpath Announce Collaboration Centered on Furthering Alzheimer’s Disease Research
The pTau217 antibody helps pinpoint pathological changes related to the disease.
In an effort to further progress neurodegenerative disease research, Alamar Biosciences, a precision proteomics company, and ALZpath, a diagnostic solutions provider for the Alzheimer’s disease space, have signed a strategic supply agreement.1
The partnership is centered around the ALZpath pTau217 (phosphorylated tau at position 217) antibody, which the parties describe as an essential component for examining Alzheimer’s alongside other neurodegenerative disorders. ALZpath pTau217 is able to provide researchers with a tool that recognizes any pathological changes related to the disease.
Per the deal, Alamar Biosciences plans to use the pTau217 antibody in its NULISAqpcr pTau-217 assay and in its multiplexed NULISAseq CNS Disease Panel 120. This collaboration brings Almar’s NULISA platform and ALZpath’s Alzheimer’s disease diagnostics capabilities to the forefront, as they look to further R&D in the space.
“We are excited to collaborate with ALZpath to provide this ultra-sensitive pTau217 assay,” commented Dr. Yuling Luo, founder, chairman, and CEO of Alamar Biosciences. “The incorporation of the ALZpath antibody into the NULISA platform provides researchers with an automated solution for both single-plex and multiplexed analysis in CNS disease research.”
A study published in JAMA Neurology2 recently revealed results surrounding the ALZpath pTau217 assay. It suggested that the ultra-sensitive immunoassay showed high diagnostic accuracy when it came to highlighting elevated levels of amyloid in the brain.
References
1. Alamar Biosciences And ALZpath, Inc. Announce Strategic Supply Agreement For PTau217 Antibody To Advance Alzheimer’s Disease Research. Alamar Biosciences. News release. February 29, 2024. Accessed March 5, 2024. https://alamarbio.com/alamar-biosciences-and-alzpath-inc-announce-strategic-supply-agreement-for-ptau217-antibody-to-advance-alzheimers-disease-research/
2. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. Published online January 22, 2024. doi:10.1001/jamaneurol.2023.5319
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
